Repligen announced its intention to acquire BioLife Solutions in a deal valued at $1.5 billion. This strategic acquisition aims to expand Repligen's presence and capabilities within the cell therapy market.

An analysis suggests that BioLife Solutions (BLFS) presents a compelling opportunity for long-term investors, highlighting factors that make it a strong hold in the market.

BioLife Solutions has set a revenue growth target of 17-20% for 2026, alongside plans to expand its commercial customer mix.

Repligen announced its intention to acquire BioLife Solutions in a $1.5 billion stock-and-cash deal. This acquisition aims to expand Repligen's cell therapy business.

Analysts provide their insights and opinions on various healthcare companies, including BioNano Genomics (BNGO) and BioLife Solutions (BLFS).

BioLife Solutions' fourth-quarter earnings call highlights have been released, summarizing the company's performance and strategic initiatives.

BioLife Solutions is rumored to be a takeover target, with Repligen identified as a potential suitor, according to recent reports.

BioLife Solutions has provided highlights from its first-quarter earnings call, covering important financial performance and business developments.

BioLife Solutions announced its latest financial results, reporting a GAAP EPS of $0.04, beating estimates by $0.06, and revenue of $24.76 million, surpassing forecasts by $0.75 million.